Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17
August 12, 2022 — 21:39 CST
This Data Is Locked!
This area is available only to Subscribers.
Novavax and partner SK bioscience will provide the first protein-based COVID-19 vaccine approved for use in adolescents aged 12 through 17 years in South Korea... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
